Stock Analiz

Century Therapeutics, Inc. IPSC

Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2021 · data as of November 13, 2026

$1.65Market cap $300M
Open the interactive analysis →

Century Therapeutics, Inc. (IPSC) is a healthcare company listed in the US with a market value of about $300M. In fiscal year 2025 it had revenue of $109M and net income of -$10M, a net margin of -8.8%.

Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -31%.

About Century Therapeutics

Century Therapeutics is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2021. Revenue went from $5M in 2022 to $109M in 2025, growth of about 175.9% a year. It was profitable in 0 of the last 6 years in our data. Its share count rose by 167% over three years (dilution for shareholders). It spends 88% of revenue on research and development.

Score: 1.2 / 5

Value0/5
Future growth4/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year
  • 5-year revenue growth above 8% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S2.7
P/B1.4
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-28.4%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)1556.8%
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-2640.8%
ROIC (5-yr avg.)-31.3%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 6 years

Fiscal year202520242023202220212020
Revenue$109M$7M$2M$5M——
Net income-$10M-$127M-$137M-$131M-$96M-$54M
Free cash flow-$105M-$110M-$102M-$17M-$134M-$51M
EPS (diluted)$-0.07$-0.81$-1.15$-1.48$-1.48$-3.58
Net margin-8.8%-1920.9%-6115.1%-2518.4%——
ROIC-8.5%-50.7%-49.7%-30.0%-17.8%—

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 4 analysts is $4.75, 188% above the current price; targets range from $2.00 to $8.00; the consensus rating is “Buy”; expected EPS is $-0.52 for the fiscal year ending December 31, 2026.

Frequently asked questions

Does Century Therapeutics pay a dividend?

Not currently.

Is Century Therapeutics a good stock to buy?

We do not give buy or sell advice. Century Therapeutics scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.